Moderna has been preparing for a global launch to introduce their COVID-19 vaccine, as the American biotech company has already received over $1.1 billion dollars in deposits from a variety of different governments. The Cambridge, Massachusetts-based company has already been in talks with the World Health Organization. There have already been supply agreements made in principle in North AMerica, the Middle East and other regions around the world.
Moderna CEO Stephane Bancel recently stated in his press release that they are “actively preparing for the launch of mRNA-1273 and have agreed multiple supply agreements with governments around the world”. He went on to add that “Moderna is committed to the highest data quality standards and scientific research as we continue to work with regulators to advance mRNA-1273”. Moderna appears to have garnered more than enough interest in their potential COVID-19 vaccine, as countries try to find any way to resume some semblance of normalcy.
American Biotech Company on the Verge of Vaccine
Moderna has been preparing for a global launch to introduce their COVID-19 vaccine, as the American biotech company has already received over $1.1 billion dollars in deposits from a variety of different governments. The Cambridge, Massachusetts-based company has already been in talks with the World Health Organization. There have already been supply agreements made in principle in North AMerica, the Middle East and other regions around the world.
Moderna CEO Stephane Bancel recently stated in his press release that they are “actively preparing for the launch of mRNA-1273 and have agreed multiple supply agreements with governments around the world”. He went on to add that “Moderna is committed to the highest data quality standards and scientific research as we continue to work with regulators to advance mRNA-1273”. Moderna appears to have garnered more than enough interest in their potential COVID-19 vaccine, as countries try to find any way to resume some semblance of normalcy.
In what has essentially become a race for who can produce the Covid vaccine, Moderna are the clear frontrunners to do so. Moderna has already gathered 30,000 participants for their late-stage vaccine trials. As of last week, more than 25,650 participants had received the second of the company’s two-dose Covid-19 vaccine. As the mRNA-1273 vaccine has begun to build up a head of steam, so have the Moderna share prices which have risen by 2% in premarket trading value.
While the rise in share value of Moderna appears to be on an upward trend, the biotech company has had a rocky third-quarter. Analysts predicted that Moderna would see a loss of 43 cents per share but were off by 16 cents as the biotech company has lost 59 cents per share during a turbulent third-quarter. Overall, the company reported a $233.6 million third-quarter loss. However, despite the obvious difficulties of the financial year, Moderna still managed to walk away with $157.9 million in revenue outperforming what Wall Street believed would be a modest $77.5 million.
As it stands, the vaccine has not yet been released and Moderna have not only had a difficult third quarter but a difficult financial year overall. However, with supply agreements in place with a multitude of different countries there is certainly a share value peak coming for the American biotech firm. Analysts are already estimating that mRNA-1273 has an estimated peak forecast of $10.6B in 2026. The overall growth between 2021 – 2026 is expected to reach 2600%. As the demand for a Covid vaccine grows, it is becoming all the more certain that we will see significant growth in the value of Moderna shares in the months and years to come.
In what has essentially become a race for who can produce the Covid vaccine, Moderna are the clear frontrunners to do so. Moderna has already gathered 30,000 participants for their late-stage vaccine trials. As of last week, more than 25,650 participants had received the second of the company’s two-dose Covid-19 vaccine. As the mRNA-1273 vaccine has begun to build up a head of steam, so have the Moderna share prices which have risen by 2% in premarket trading value.
While the rise in share value of Moderna appears to be on an upward trend, the biotech company has had a rocky third-quarter. Analysts predicted that Moderna would see a loss of 43 cents per share but were off by 16 cents as the biotech company has lost 59 cents per share during a turbulent third-quarter. Overall, the company reported a $233.6 million third-quarter loss. However, despite the obvious difficulties of the financial year, Moderna still managed to walk away with $157.9 million in revenue outperforming what Wall Street believed would be a modest $77.5 million.
As it stands, the vaccine has not yet been released and Moderna have not only had a difficult third quarter but a difficult financial year overall. However, with supply agreements in place with a multitude of different countries there is certainly a share value peak coming for the American biotech firm. Analysts are already estimating that mRNA-1273 has an estimated peak forecast of $10.6B in 2026. The overall growth between 2021 – 2026 is expected to reach 2600%. As the demand for a Covid vaccine grows, it is becoming all the more certain that we will see significant growth in the value of Moderna shares in the months and years to come.
